Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego · 2025
The effect of the phytotherapeutic agent Desolis on the cytokine profile in the secretion of paraurethral glands in the complex treatment of women with chronic urethritis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tsiporenko Serhii Yu, Babinets Liliia S, Doroshenko Maksym M, Gudzenko Andrii V
Аннотация
OBJECTIVE: Aim: To investigate the effect of the phytotherapeutic agent Desolis on cytokine profiles in the secretion of paraurethral glands as part of combination therapy in women with chronic urethritis.
PATIENTS AND METHODS: Materials and Methods: A total of 79 women with chronic urethritis were examined and divided into two groups. The main group (n=40) received standard etiological therapy in accordance with CDC guidelines along with Desolis (administered orally twice daily for 10 days). The control group (n=39) received standard treatment only. Cytokine concentrations in the secretion of the paraurethral glands were determined before and after treatment using ELISA.
RESULTS: Results: Women with chronic urethritis demonstrated significantly elevated levels of pro-inflammatory cytokines (IL-8, IFN-γ, IP-10) and reduced concentrations of IL-2, IL-1β, RANTES, and Fractalkine. The addition of Desolis to treatment led to normalization of these markers, which did not differ significantly from reference values (p>0.05), unlike the control group. Furthermore, patients in the Desolis group experienced a shorter duration of clinical symptoms and significantly higher pathogen elimination rates (87.5% vs. 56.4%, p<0.05).
CONCLUSION: Conclusions: The use of Desolis in combination therapy contributes to the normalization of the local cytokine profile, improves clinical outcomes, and increases treatment efficacy in women with chronic urethritis.
PATIENTS AND METHODS: Materials and Methods: A total of 79 women with chronic urethritis were examined and divided into two groups. The main group (n=40) received standard etiological therapy in accordance with CDC guidelines along with Desolis (administered orally twice daily for 10 days). The control group (n=39) received standard treatment only. Cytokine concentrations in the secretion of the paraurethral glands were determined before and after treatment using ELISA.
RESULTS: Results: Women with chronic urethritis demonstrated significantly elevated levels of pro-inflammatory cytokines (IL-8, IFN-γ, IP-10) and reduced concentrations of IL-2, IL-1β, RANTES, and Fractalkine. The addition of Desolis to treatment led to normalization of these markers, which did not differ significantly from reference values (p>0.05), unlike the control group. Furthermore, patients in the Desolis group experienced a shorter duration of clinical symptoms and significantly higher pathogen elimination rates (87.5% vs. 56.4%, p<0.05).
CONCLUSION: Conclusions: The use of Desolis in combination therapy contributes to the normalization of the local cytokine profile, improves clinical outcomes, and increases treatment efficacy in women with chronic urethritis.